Cyclo Therapeutics jumps on seeking FDA nod for mid-stage Alzheimer's drug trial

Cyclo Therapeutics

16/11/2021 13:48

** Shares of drug developer  CYTH.O  up ~18.5% at $8.64
pre-market, their highest in nearly four months
    ** Co submits application to the U.S. FDA to initiate human
mid-stage trials for its lead drug candidate - Trappsol Cyclo,
in treating early Alzheimer's Disease (AD)  urn:newsml:reuters.com:*:nBw2J1Kbpa
    ** The drug has shown encouraging results to effectively
manage transportation of cholesterol in AD patients - CYTH
    ** Says cholesterol imbalance can worsen the condition of
patients 
    ** Earlier this year, CYTH also launched a late-stage study
to test Trappsol Cyclo in treating a type of progressive genetic
disorder   urn:newsml:reuters.com:*:nL3N2NZ3FN
    ** Up to Monday's close, stock up 67.59% YTD  

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))